Go to main page

Scientific Poster:

Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology

Download this poster now

Poster: Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology
    You may unsubscribe from these communications at any time. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. For more information on our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology

Type 1 diabetes, also called Juvenile diabetes, is an auto-immune condition where the pancreas produces little or no insulin. The only known treatment involves insulin administration which manages the symptoms without treating the cause. Methyldopa has been shown to re-program T-cells, which protect the islet cells in the pancreas from destruction. Absorption is limited to 50% in oral doses in the upper gastrointestinal tract. Hence, a gastro-retentive dosage form is required to increase absorption efficiency of methyldopa.

Ruchit Trivedi, David Zama, Mark Previti, and J. Blair West

Poster on formulation of a novel gastro-retentive sustained release oral formulation for methyldopa to treat Type I diabetes, presented by Ruchit Trivedi, Ph. D.,  at AAPS 2016.